| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | AZD-7545 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.3 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.03 | 0.3 |